Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a single chat with a partner keep people who inject drugs in care?

NCT ID NCT07631559

Knowledge-focused Sponsor: University of California, San Francisco Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tests a one-time 'booster' session for people who inject drugs and their injecting partners, given right after finishing hepatitis C treatment. The session helps them set health goals, identify barriers, and improve communication to stay engaged in ongoing healthcare. Researchers will enroll 50 adults in San Francisco to see if the session is acceptable and feasible.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
partner navigation intervention booster session
What this could lead to
If successful, this could point toward a simple, low-cost way to help people who inject drugs stay connected to healthcare after finishing hepatitis C treatment.
What could go wrong
This is a very small pilot study (50 people) testing only feasibility and acceptability, not whether the session actually improves health. It may not work in other settings or populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: For index participants: * 18 years of age or older at enrollment * History of injecting drug use * Completed HCV treatment within the past 3 months * Report a primary injecting partner willing to participate * Willing and able to provide informed consent * English or Spanish speaking For primary injecting partners: * Primary injecting partner of an enrolled index participant: * 18 years of age or older at enrollment * Willing and able to provide informed consent * English or Spanish speaking * has context menu Exclusion criteria: For both index participants and injecting partners: * Unable to provide informed consent due to cognitive impairment or acute intoxication at the time of enrollment * Previously participated in this study in any capacity

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Drug use disorders are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Harm Reduction hepatitis C virus infection opiate dependence substance-related disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Drug use disorders Harm reduction Healthcare access Hepatitis C (HCV) Opioid-use disorder Substance use disorder (SUD)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Quaker Meeting House

    San Francisco, California, 94103, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.